From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation

PROTAC is a rapidly developing engineering technology for targeted protein degradation using the ubiquitin-proteasome system, which has promising applications for inflammatory diseases, neurodegenerative diseases, and malignant tumors. This paper gives a brief overview of the development and design...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 17; no. 1; p. 100
Main Authors Wang, Siqi, He, Fuchu, Tian, Chunyan, Sun, Aihua
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.01.2024
MDPI
Subjects
Androgens
Breast cancer
Cell growth
Clinical trials
Design
Drug dosages
Drug resistance
Enzymes
Estrogens
Kinases
Metastasis
Nervous system diseases
Peptides
Physiology
Prostate cancer
PROTAC
protein-hydrolysis-targeted chimeras
Proteins
Proteolysis
Review
targeted protein degradation
TPD
Ubiquitin
ubiquitin–proteasome system
protein-hydrolysis-targeted chimeras
TPD
targeted protein degradation
ubiquitin–proteasome system
PROTAC
Online AccessGet full text

Cover

More Information
Summary:PROTAC is a rapidly developing engineering technology for targeted protein degradation using the ubiquitin-proteasome system, which has promising applications for inflammatory diseases, neurodegenerative diseases, and malignant tumors. This paper gives a brief overview of the development and design principles of PROTAC, with a special focus on PROTAC-based explorations in recent years aimed at achieving controlled protein degradation and improving the bioavailability of PROTAC, as well as TPD technologies that use other pathways such as autophagy and lysosomes to achieve targeted protein degradation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1424-8247
1424-8247
DOI:10.3390/ph17010100